BIODELIVERY SCIENCES INTERNATIONAL INC 4
4 · BIODELIVERY SCIENCES INTERNATIONAL INC · Filed Oct 4, 2005
Insider Transaction Report
Form 4
Poole William
Director
Transactions
- Purchase
Common Stock
2005-09-30$1.85/sh+5,000$9,250→ 5,000 total
Holdings
- 4.25
Series A Preferred
Exercise: $4.25→ Common Stock (3,190 underlying) - 0
Option
Exercise: $2.94From: 2005-07-28Exp: 2015-07-28→ Common Stock (35,000 underlying)
Footnotes (3)
- [F1]One share of common stock for one share of preferred stock
- [F2]The Series A Preferred will be convertible into shares of the Company's common stock (the "Common Stock") on a one for one basis. The Series A Preferred is eligible for conversion upon the earlier to occur of: (i) FDA approval of Arius' first proposed product (ii) 30 days notice to the Company of a Conjversion Event (hereinafter defined) or (iii) five years from the closing date of the Transaction. The term "Conversion Event" is defined in the Certificate of Designation of the Series A Preferred to mean the failure of the Company to provide at least $3,000,000 to Arius as required to: (i) pay Atrix Laboratories , Inc. ("Atrix") $1,000,000 by August 24, 2004 pursuant to the terms of a license agreement between Arius and Atrix and (ii) fund, in a total amount of no less than $2,000,000, the operations of Arius.
- [F3]Not applicable